Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients "NEURO-XAR"

Completed

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Male and female patients ≥ 18 years old who start treatment with rivaroxaban
- Non-valvular Atrial Fibrillation is documented in patients' file
- Prior TIA/Stroke history
- TIA - more than 72 hours after documented TIA
- more than 2 weeks after non-hemorrhagic stroke
- Written informed consent

Exclusion Criteria

- Contraindications for use of Xarelto® in accordance with approved product label
- Previous thromboprophylaxis treatment with anticoagulants prior toby reason of stroke / TIA prevention
- Any reasons of medical and non-medical character, which in the opinion of the physician can hamper patient participation in NIS